HEV IgG ELISA Kit (DEIA1905)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
plasma, serum
Species Reactivity
Human
Intended Use
Third generation Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgG antibodies to Hepatitis E Virus in human plasma and sera.
The kit may be used for the screening of blood units and the follow-up of HEV-infected patients.
Contents of Kit
1. Microplate, 12 strips of 8 microwells
2. Negative Control, 1 x 2.0 mL/vial
3. Positive Control, 1 x 2.0 mL/vial
4. Calibrator, 1 vial. Lyophilized calibrator.
5. Wash buffer concentrate, 1 x 60 mL/bottle. 20X concentrated solution.
6. Enzyme Conjugate, 1 x 16 mL/vial.
7. Chromogen/Substrate, 1 x 16 mL/vial. Ready-to-use component.
8. Assay Diluent, 1 x 8 mL/vial.
9. Sulphuric Acid, 1 x 15 mL/vial.
10. Sample Diluent, 1 x 50 mL/vial.
11. Plate sealing foils
12. Package insert
Storage
For more detailed information, please download the following document on our website.
Sensitivity
A diagnostic sensitivity of 100% was found.

Citations


Have you cited DEIA1905 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


HEV Occurrence in Waste and Drinking Water Treatment Plants

FRONTIERS IN MICROBIOLOGY

Authors: Cuevas-Ferrando, Enric; Randazzo, Walter; Perez-Cataluna, Alba; Sanchez, Gloria

Hepatitis E virus (HEV), particularly zoonotic genotype 3, is present in environmental waters worldwide, especially in industrialized countries. Thus, monitoring the presence of HEV in wastewater treatment plants (WWTPs) is an emerging topic due to the importance of reusing water on a global level. Given the limited data, this study aimed to monitor the occurrence of HEV in influent and effluent water in waste- and drinking-water treatment plants (WWTPs and DWTPs). To this end, different procedures to concentrate HEV in influent and effluent water from WWTPs and DWTPs were initially evaluated. The evaluated procedures resulted in average HEV recoveries of 15.2, 19.9, and 16.9% in influent, effluent, and drinking water samples, respectively, with detection limits ranging from 10(3) to 10(4) international units (IU)/L. Then, a one-year pilot study was performed to evaluate the performance of the selected concentration method coupled with three RT-qPCR assays in influent and effluent water samples from four different WWTPs. HEV prevalence in influent water varied based on both the RT-qPCR assay and WWTP, while HEV was not detected in effluent water samples. In addition, HEV prevalence using only RT-qPCR3 was evaluated in influent (n = 62) and effluent samples (n = 52) from four WWTPs as well as influent (n = 28) and effluent (n = 28) waters from two DWTPs. The present study demonstrated that HEV circulated in the Valencian region at around 30.65% with average concentrations of 6.3 x 10(3) IU/L. HEV was only detected in influent wastewater samples, effluent samples from WWTPs and influent and effluent samples from DWTPs were negative. However, given that the infective dose in waterborne epidemics settings is not yet known and the low sensibility of the assay, unfortunately, no direct conclusion could be achieved on the risk assessment of environmental contamination.

Noninvasive models for predicting poor prognosis of chronic HBV infection patients precipitating acute HEV infection

SCIENTIFIC REPORTS

Authors: Li, Qiang; Chen, Chong; Huang, Chenlu; Xu, Wei; Hu, Qiankun; Chen, Liang

Hepatitis E virus (HEV) infection contributes to a considerable proportion of acute-on-chronic liver failure (ACLF) in patients with chronic hepatitis B virus (HBV) infection. This study aimed to predict the prognosis of chronic HBV infection patients precipitating acute HEV infection. A total of 193 patients were enrolled in this study. The performances of three chronic liver disease prognostic models (CTP score, MELD score, and CLIF-C ADs) were analyzed for predicting the development of ACLF following HEV superimposing chronic HBV infection. Subsequently, the performances of five ACLF prognostic assessment models (CTP score, MELD score, CLIF-C ACLFs, CLIF-C OFs, and COSSH-ACLFs) were analyzed for predicting the outcome of those ACLF patients. Of 193 chronic HBV infection patients precipitating acute HEV infection, 13 patients were diagnosed ACLF on admission, 54 patients developed to ACLF after admission, and 126 patients had non-ACLF during the stay in hospital. For predicting the development of ACLF, CTP score yielded a significantly higher AUROC compared with MELD score and CLIF-C ADs (0.92, 0.88, and 0.86, respectively; all p < 0.05). For predicting the poor prognosis of ACLF patients, the COSSH-ACLFs yielded a significantly higher AUROC compared with CLIF-C ACLFs, CLIF-C OFs, MELD score, and CTP score (0.89, 0.83, 0.81, 0.67, and 0.58, respectively; all p < 0.05). In conclusion, the stepwise application of CTP score and COSSH-ACLFs can predict the prognosis of chronic HBV infection patients precipitating acute HEV infection.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket